Citations

Showing 10 of 108083 citations.

Engineering an RNA virus as a vector for targeted cellular immunity (53.8)
Bell, Michael , Allen, Kathleen, Hansen, Michael J. , Pease, Larry R. , Pavelko, Kevin D. , Bell, Michael

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 188 | Issue: 1_Supplement | Pages: 53.8-53.8

10.4049/jimmunol.188.supp.53.8 Get It

Abstract One limitation to the development of targeted tumor immunity is the availability of safe vectors that can drive strong T-cell responses capable of eradicating tumors. We have designed viral vectors using Theiler’s murine encephalomyelitis virus (TMEV) that effectively inhibit melanoma outgrowth. By cloning the TMEV genome into a eukaryotic expression vector that can easily be manipulated we were able to generate several novel tumor specific virus vaccines. We find that incorporation of defined MHC class I epitopes into sites within the leader protein of the virus can drive strong CD8+ T-cell responses against these target peptides. Further, we find that the site of incorporation can change the elicited cytokine profile and the virulence of the virus. Incorporation of the ovalbumen peptide after the third amino acid of the L protein (p3) generates a strong IFNβ response, whereas insertion within the downstream XhoI restriction site elicits a strong IL6 response similar to wild-type TMEV. Further, the p3 virus is not lethal to RAG-deficient mice, where the XhoI and wild-type TMEV virus are. However, p3 virus persists and kills IFNα/β receptor-deficient mice, suggesting that innate immune responses are responsible for viral clearance. In spite of these differences the p3 and XhoI viruses can stimulate antigen specific T-cell responses and inhibit tumor outgrowth equivalently, demonstrating the efficacy of TMEV and its potential as a therapeutic intervention.
Contribution of an aging environment towards a proinflammatory tumor-like milieu (54.4)
Mirza, Noweeda, Pollock, Kevin G. , Lustgarten, Joseph, Cohen, Peter A. , Gendler, Sandra , Hoelzinger, Dominique B. , Myers, Cheryl , Pollock, Kevin, Dominguez, Ana Lucía

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 188 | Issue: 1_Supplement | Pages: 54.4-54.4

10.4049/jimmunol.188.supp.54.4 Get It

Abstract Chronic inflammation associated with aging is termed inflamm-aging. It manifests as a rise in many proinflammatory mediators and contributes to a decline in immune function. Unregulated inflammasome activation initiates an inappropriate inflammatory response. It is particularly imperative to understand inflammasome dysregulation in the elderly (>65 yrs), since it is a likely basis of immune dysfunction. Analyses of freshly isolated memory CD4+ and CD8+ splenic T cells demonstrated that even without further activation, inflammasome genes were already significantly up-regulated in old mice compared to young, including factors critical to myeloid-derived suppressor cell (MDSC) expansion including S100a8, S100a9, IL-1β, IL-13 and IL-6. A corresponding 2-3 fold increase in CD11b+Gr1+cells was observed in the spleens of old naïve mice compared to young. Importantly, cells with the CD11b+Gr1+ phenotype from old mice, unlike young, were functionally MDSCs and suppressed T cell proliferation. Therefore, the immunosuppressive environment of the tumor-bearing host also appears to be operative in aging, even in the absence of tumor. We hypothesize that constituitive activation of inflammasome complex results in a chronic inflammatory state, altering immune responses in the elderly similarly to the tumor-bearing state. Preemptive reversal of inflammasome-induced MDSCs may enhance T cell immunosurveillance in the elderly, a population with a heightened susceptibility to malignancy.
Elevated IL -1β levels are associated with resistance to Yesinia pestis in B10.T(6R) mice (55.11)
Sarkar, Sanghita , Lambert, Nathaniel, Bradley, David S., Nilles, Matthew L.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 188 | Issue: 1_Supplement | Pages: 55.11-55.11

10.4049/jimmunol.188.supp.55.11 Get It

Abstract We have previously demonstrated that inbred B10.T(6R) mice are resistant to Yesinia pestis (KIM5 strain) and resistance decreases with age. It has been shown that Y. pestis is cleared by neutrophil engulfment. We evaluate here the potential contribution of IL-1β, a proinflammatory cytokine important for neutrophil recruitment and activation. IL-1β levels were measured from spleens and sera collected 60 and 72 hour post infection from young (resistant) and middle-aged (susceptible) B10.T(6R) mice and control (susceptible) C57BL/6. Splenic IL-1β production was statistically higher in young B10.T(6R), compared with both middle-aged B10.T(6R) and C57BL/6 mice. Serum IL-1β levels were also moderately higher in young B10.T(6R) mice when compared to middle aged B10.T(6R) and C57BL/6 mice. IL-1β produced by Y. pestis-infected peritoneal-derived macrophages taken from uninfected young and middle-aged B10.T(6R) mice and C57BL/6 mice was measured at 2,4,8 and 24 hour. IL-1β levels were significantly elevated in peritoneal macrophages infected in vitro from young B10.T(6R) mice compared to decreased levels in both middle-aged B10.T(6R) and C57BL/6 derived peritoneal macrophages. These studies suggest a direct correlation between elevated IL-1β levels and resistance to Y. pestis infection observed in young B10.T(6R) mice.
HLA alleles not associated with arthritis predispose by forming HLA- DQbeta-DQalpha trans-heterodimer (93.27)
Behrens, Marshall D., David, Chella S., Taneja, Veena

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 184 | Issue: Supplement_1 | Pages: 93.27-93.27

10.4049/jimmunol.184.supp.93.27 Get It

Abstract HLA-DQB1*0302/DQA1*0301 renders humans and transgenic mice susceptible to develop arthritis while HLA-DQB1*0601/DQA1*0103 has been associated with resistance to arthritis in both. However, some patients of rheumatoid arthritis carry the non-associated alleles. Most of the studies do not take in to account the role of DQA1 alleles. DQB1*0604 generally occurs in linkage with DQA1*0102. To understand the role of trans-heterodimer, we generated DQB1*0604/ DQA1* 0103 transgenic mice lacking endogenous class II molecules. Previous studies have shown that DQB1*0601/DQA1*0103 transgenic mice are resistant to develop collagen-induced arthritis. The DQB1*0604/A1*0103 and DQA1*0103 mice developed severe arthritis and generated antigen-specific response in vitro. The DQB1*0604/ DQA1*0103 could present CII-derived peptides that are not presented by RA resistant DQ6 allele suggesting that trans-heterodimer molecules between two DQB1 and DQA1 molecules may result in presentation of unique antigens and susceptibility to develop arthritis. The data provides a possible explanation for the presence of HLA alleles not associated with arthritis in some patients.
Uveitis-associated epitopes of retinal antigens are pathogenic in the humanized mouse model of EAU and identify autoaggressive T cells (93.1)
Silver, Phyllis B., Horai, Reiko , McDowell, Hugh, Chan, Chi‐Chao , Kwok, William W. , David, Chella S., Mattapallil, Mary J. , Mattapallil, Joseph J. , Karabekian, Zaruhi , James, Eddie A. , Caspi, Rachel R

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 184 | Issue: 1_Supplement | Pages: 93.1-93.1

10.4049/jimmunol.184.supp.93.1 Get It

Abstract Autoimmune uveitis affects 150,000 Americans annually and is a leading cause of blindness. Pathogenesis is thought to involve T cell mediated responses to retinal proteins, such as retinal arrestin (S-Ag). Susceptibility to autoimmune uveitis is strongly associated with HLA class I and class II, but relatively little is known about the nature of HLA class II alleles and about the epitopes that might be pathogenic in the context of different HLA class II molecules. Using a ‘humanized’ mouse model for experimental autoimmune uveitis (EAU) in HLA transgenic mice, we have identified permissive and non-permissive alleles of the HLA-DR and -DQ genes and characterized allele-specific uveitogenic epitopes. The sequences of these epitopes overlap with some of the previously identified peptides of S-Ag (M and N), which elicit memory responses in lymphocytes of uveitis patients. HLA-DR restricted S-Ag specific CD4+ T cells could be detected in blood and draining lymph nodes of immunized mice using HLA class II tetramers, demonstrating the potential use of this reagent to detect and isolate antigen specific T cells in uveitis patients. Our data provide new insights into the pathogenesis of human uveitis, and may help in the development of antigen specific therapies.
Development and Maintenance of Antiviral Antibody Secreting Cells in Response to Influenza Virus Infection (92.3)
Wolf, Amaya I. , Mozdzanowska, Krystyna, Metzgar, Michele H., Bram, Richard J. , Erikson, Jan, Quinn, William J. , Cancro, Michael P.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 184 | Issue: 1_Supplement | Pages: 92.3-92.3

10.4049/jimmunol.184.supp.92.3 Get It

Abstract Respiratory infection with influenza virus (flu) induces long-lasting protective humoral immunity. Although flu-specific antibody secreting cells (ASCs) increase post infection (p.i.) and are present in various organs, including the lung, it is unclear what signals promote their maintenance and/or survival. We determined that flu-specific ASCs were maintained in the lung up to half a year p.i.. These cells were not proliferating as they failed to incorporate BrDU. With the hypothesis that BLyS-family members may be important for ASC maintenance, we investigated the B cell response to flu in TACI-/- mice. TACI has been implicated in the T-independent type II response, but its role in anti-viral immunity is unknown. WT and TACI-/- mice exhibited a similar anti-flu B cell response at day 8 p.i., however, by day 33p.i., TACI-/- mice had significantly lower anti-flu antibody levels in the serum and locally in the lung. TACI deficiency did not affect flu-specific ASC numbers in spleen and lung-draining mediastinal lymph nodes. In contrast, it resulted in drastically reduced ASCs in lung and bone marrow. The results of our study will be discussed in the context of protection and possible implications for vaccine development.
Restrictions in the repertoire of allospecific T cells. Contribution of the alpha-helical sequence polymorphism of HLA-DR molecules.
Xie, Chunguang , Weyand, Cornelia M., Goronzy, Jörg J. , Xie, C, Hu, William T. , Lundy, Steven K.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 151 | Issue: 2 | Pages: 825-836

10.4049/jimmunol.151.2.825 Get It

Abstract We have studied the molecular diversity of the allogeneic TCR repertoire specific for the HLA-DR4 variant, DRB1*0404, by analyzing the V beta gene segment usage of CD4+ T cell clones from nine different donors and comparing the V beta repertoire in allospecific and unselected T cell populations. To investigate the forces shaping the repertoire of the alloreactive T cell response we compared the diversity of TCR specificities utilized in very similar and in disparate responder/stimulator combinations. Six of the responders shared the HLA-DRB1*0401 allele, which differs from the HLA-DRB1*0404 allele by only two amino acid substitutions at positions 71 and 86 of the HLA-DR beta 1 chain; three responders expressed HLA-DRB1 alleles with extensive polymorphisms compared with the stimulator HLA-DRB1 allele. In all nine responders, TCR specificities recruited to recognize HLA-DRB1*0404 were strongly biased toward the dominant usage of one to three V beta elements. Despite some degree of heterogeneity between different responders, the overall pattern was very similar with a hierarchy of TCR V beta elements expressed by HLA-DRB1*0404 specific T cells. A core group of V beta elements (V beta 6, 5, 2, 13.2, 18, and 7) was preferentially used, whereas other V beta elements including V beta 3, 4, and 8 were infrequently used or not used at all. Sequencing of the VDJ beta region from selected T cell clones showed no junctional bias associated with the preferential V beta gene segment usage. Surprisingly, the T cell diversity in focused and in complex alloreactive responses were equally biased. The finding that HLA-DR4+ and DR4- donors exhibited a similar bias supports the interpretation that the alpha-helical HLA-DR structure of the stimulator cell has a dominant contribution in shaping the alloreactive repertoire.
A CD28 based bi-directional molecular bridge that support plasma cell survival in the bone marrow. (46.16)
Murray, Megan , Koorella, Chandana, Rozanski, Cheryl, Carlson, Louise, Shaughnessy, John D., Nair, Jayakumar R. , Rozanski, Cheryl, Bergsagel, P. Leif , Boise, Lawrence , Lee, Kelvin H.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 188 | Issue: 1_Supplement | Pages: 46.16-46.16

10.4049/jimmunol.188.supp.46.16 Get It

Abstract Dendritic cells (DC) are essential for the long term survival of plasma cells (PC) in the bone marrow and for the maintenance of persistent antibody titers. But the molecular basis for these interactions is not very clear. Both normal and malignant PC (like myeloma) express the T-cell co-stimulatory molecule CD28. Our data show that CD28 expressed on PC play a major role in CD80/CD86 (B7) mediated DC induction of growth factors such as IL-6 and immunosuppressive enzyme indoleamine 2,3 dioxygenase (IDO) as well as in antibody or DC mediated protection of PC in vitro. While IL-6 protected PC in vitro, IDO induced the formation of regulatory T cells in culture. Use of myeloma drug lenalidomide to inhibit DC-B7 expression or anti-CD28(Fab)2 fragments to block CD28-B7 interactions reduced DC ability to protect MM cells or produce IL-6/IDO. Moreover, just like in T-cell models, CD28 activation in malignant PC triggers similar molecular events such as tyrosine phosphorylation and association of p85. We believe that downstream of CD28, while PI3K/Akt governs survival, the Vav1/SLP76 pathway regulate PC proliferation and these form the molecular basis for a bi-directional molecular bridge between the PC and bone marrow microenvironment. Targeting this bridge could form the basis for future therapeutic strategies. Our data suggests a role for CD28-B7 in plasma cell survival by modulating the bone marrow microenvironment.
Critical function of CCL1 in the maintenance of T regulatory cell’s suppressive role. (66.14)
Lustgarten, Joseph, Hoelzinger, Dominique B. , Dominguez, Ana

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 186 | Issue: 1_Supplement | Pages: 66.14-66.14

10.4049/jimmunol.186.supp.66.14 Get It

Abstract T-regulatory cells (Tregs) create an immunosuppressive environment that reduces the efficacy of anti-tumor immunotherapy. Depletion of Tregs enhances anti-tumor immune responses, but also affects T-effector cells. Previously we showed that blockade of chemokine ligand 1 (CCL1) inhibits Treg conversion, their suppressive function, and in combination with intra-tumoral CpG-ODN results in complete rejection of tumors in BALB-NeuT tolerant mice. Most importantly, this therapeutic combination does not affect T-effector function and increases tumor-lytic CD8+NKG2D+ cells within the tumor. Here we expand on the role of blocking CCL1 in enhancing anti-tumor immunotherapy. Using CCL1 knockout (CCL1ko) mice, we found no impairment in TGFβ dependent de novo Treg conversion, however CCL1ko Tregs are less suppressive in vitro, than their wild type counterparts. CCL1ko mice treated with intratumoral CpG showed a marked reduction in tumor growth and a significant increase in tumor rejection as compared to similarly treated C57b control mice. Examination of lymphocyte populations within B16 and MucI tumors showed elevated levels of CD8+ cells. Finally the evaluation of levels of intra-tumoral cytokines and chemokines revealed elevated levels of IFNγ, CXCL9, CCL3 and CXCL10 in tumors grown in CCL1ko mice, suggesting a pro-inflammatory environment. Taken together these data support the role of CCL1as a critical factor for the maintenance of the suppressive function of Tregs.
Dendritic cells support long term survival of plasma cells via CD28-CD80/CD86 interactions (66.11)
Carlson, Louise, Rozanski, Cheryl, Koorella, Chandana, Murray, Megan , Shaughnessy, John Jr, Chanan‐Khan, Asher , Nair, Jayakumar R. , Rozanski, Cheryl, Shaughnessy, John P., Bergsagel, P. Leif , Boise, Lawrence , Lee, Kelvin H.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 186 | Issue: 1_Supplement | Pages: 66.11-66.11

10.4049/jimmunol.186.supp.66.11 Get It

Abstract We have previously shown (AAI2009) that dendritic cells (DC) contribute to the survival of long lived plasma cells in the bone marrow, which are important to maintain persistent antibody titres. What is not clear are the molecular interactions that are involved. Both normal and malignant plasma cells(like myeloma cells) express the T-cell co-stimulatory molecule CD28, and both interact with DCs in the bone marrow microenvironment. CD28 activation on MM triggers similar molecular partners downstream as observed in T-cells. Gene expression analysis of normal and malignant plasma cells shows that CD28 expression correlates with poor prognostic subgroups that are associated with specific genetic lesions. In our data, while activation of CD28 with antibodies or DC-CD80/CD86 (B7) protects myeloma cells against cell death, the ligation of B7 on DCs induces DC production of plasma cell survival factor IL-6, and immunosuppressive factor indoleamine 2,3-dioxygenase (IDO). Use of Lenalidomide (a common myeloma drug) to inhibit DC-B7 expression or anti-CD28(Fab)2 fragments to block CD28-B7 interactions reduced DC ability to protect MM cells. Experiments with αCD28(Fab)2 or inhibitors of notch pathway suggest a cross talk that regulates IL-6 production. IDO activity in DC-MM cocultures, suppressed T-cell proliferation in MLRs while an IDO inhibitor alleviated this. Our data suggests a role for CD28-B7 in plasma cell survival by modulating the bone marrow microenvironment.